
To identify a recommended phase II dose for the second generation zzso zzso zzso zzso zzso zzso administered by intravenous zzso every 3 weeks without folate supplementation and to describe zzso zzso 

Adults with advanced zzso were enrolled in zzso of three per dose level with expansion to six upon observation of zzso toxicity zzso The maximum tolerated dose zzso was defined as the dose at which two of up to six patients experienced zzso Upon identification of an zzso and evidence of cumulative zzso a lower intermediate dose was explored as a candidate phase II zzso zzso plasma zzso were measured using an zzso zzso 

The recommended phase II dose is zzso zzso zzso were zzso zzso zzso zzso zzso fatigue, and zzso zzso were modestly cumulative over three zzso zzso analysis showed a zzso relationship and a progressive increase in zzso zzso over three zzso Both zzso and zzso factors may contribute to the modest cumulative toxicity observed with zzso 

